Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published September 19, 2007 | Published + Supplemental Material
Journal Article Open

Nicotine-Induced Dystonic Arousal Complex in a Mouse Line Harboring a Human Autosomal-Dominant Nocturnal Frontal Lobe Epilepsy Mutation

Abstract

We generated a mouse line harboring an autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) mutation: the α4 nicotinic receptor S248F knock-in strain. In this mouse, modest nicotine doses (1–2 mg/kg) elicit a novel behavior termed the dystonic arousal complex (DAC). The DAC includes stereotypical head movements, body jerking, and forelimb dystonia; these behaviors resemble some core features of ADNFLE. A marked Straub tail is an additional component of the DAC. Similar to attacks in ADNFLE, the DAC can be partially suppressed by the sodium channel blocker carbamazepine or by pre-exposure to a very low dose of nicotine (0.1 mg/kg). The DAC is centrally mediated, genetically highly penetrant, and, surprisingly, not associated with overt ictal electrical activity as assessed by (1) epidural or frontal lobe depth-electrode electroencephalography or (2) hippocampal c-fos-regulated gene expression. Heterozygous knock-in mice are partially protected from nicotine-induced seizures. The noncompetitive antagonist mecamylamine does not suppress the DAC, although it suppresses high-dose nicotine-induced wild-type-like seizures. Experiments on agonist-induced ⁸⁶Rb⁺ and neurotransmitter efflux from synaptosomes and on α4S248Fβ2 receptors expressed in oocytes confirm that the S248F mutation confers resistance to mecamylamine blockade. Genetic background, gender, and mutant gene expression levels modulate expression of the DAC phenotype in mice. The S248F mouse thus appears to provide a model for the paroxysmal dystonic element of ADNFLE semiology. Our model complements what is seen in other ADNFLE animal models. Together, these mice cover the spectrum of behavioral and electrographic events seen in the human condition.

Additional Information

© 2007 Society for Neuroscience. Received Nov. 21, 2006; revised Aug. 1, 2007; accepted Aug. 1, 2007. This work was supported by National Health and Medical Research Council (NHMRC) Program Grant 236805 and National Institutes of Health Grant MH53631 to J.M.M.; National Institute on Drug Abuse Grants DA003194, DA012242, and DA015663; National Institute of Neurological Disorders and Stroke Grants NS43800 and NS046464; and Science Foundation Ireland Grant 02-1N1B227. J.D. is an NHMRC Practitioner fellow. We thank Vincenzo Ferreri, Jim Massalas, Keith Buxton, and Yvette Wilson for technical assistance and Dr. Rachael Nally and Associate Prof. Ian Gordon for advice with statistical analysis. We are grateful to Dr. Jim Boulter for providing genomic DNA clones used to build the original L9S' targeting construct. We are grateful to Prof. Ingrid Scheffer for critical input and discussion on clinical aspects of ADNFLE.

Attached Files

Published - 10128.full.pdf

Supplemental Material - Human_ADNFLE_video.mpg

Supplemental Material - S248F_DAC1_video.mpg

Supplemental Material - S248F_DAC2.mpg

Files

10128.full.pdf
Files (31.0 MB)
Name Size Download all
md5:1182524670d9939eee6303d09bed397d
7.4 MB Download
md5:6ee3f4150519fc5e32762159c48404b7
12.3 MB Download
md5:72386f7b03154b975527255d68ee492a
543.7 kB Preview Download
md5:fda6c64a7ab7097086ba7bbeca61db35
10.8 MB Download

Additional details

Created:
August 22, 2023
Modified:
October 20, 2023